{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:29:22Z","timestamp":1787070562318,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The glycopeptide antibiotic teicoplanin (TEIC) is used to treat infections caused by methicillin-resistant Staphylococcus aureus and other gram-positive bacteria. Because higher target trough concentrations are now recommended, higher loading dose (LD) regimens have been proposed. However, the factors affecting trough concentration (Ctrough) levels and the safety of high-dose regimens remain unclear. This study aimed to investigate the factors that should be considered in the LD regimen of TEIC in pediatric patients and assess the safety of a higher LD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled pediatric patients aged 1-14\u00a0years with available TEIC concentrations measured between August 2013 and December 2024. Factors affecting the initial Ctrough and the initial Ctrough divided by LD per kilogram of body weight (C\/D ratio) were investigated. Safety assessment included serious adverse reactions at the time of initial Ctrough measurement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 108 patients were enrolled in this study. Of 108 enrolled patients, 64 patients were measured initial Ctrough on day 4. Fifty-four patients received higher LD (average 54.2\u00a0mg\/kg\/3\u00a0days) than the standard regimen, with 33 patients (52%) not achieving an initial Ctrough of 15\u00a0\u03bcg\/mL. Linear regression analysis showed that the initial Ctrough was associated with age (P\u2009=\u2009.008), estimated glomerular filtration rate (eGFR; P\u2009&amp;lt;\u2009.001), and serum albumin level (P\u2009=\u2009.017). The C\/D ratio on day 4 was associated with eGFR (P\u2009&amp;lt;\u2009.001) and the presence or absence of febrile neutropenia (FN) (P\u2009=\u2009.046). Further analysis restricted to patients with FN indicated that bone marrow transplantation (BMT) (P\u2009=\u2009.046) affected the C\/D ratio. Serious adverse reactions occurred in 5 cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical conditions, such as FN and BMT, which cause an increase in eGFR, may affect the initial Ctrough in pediatric patients. Moreover, a higher LD was well-tolerated. When determining the LD, clinical conditions must be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpids\/piag069","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:17:47Z","timestamp":1786101467000},"source":"Crossref","is-referenced-by-count":0,"title":["Factors Affecting the Initial Serum Concentration of Teicoplanin in Pediatric Patients: A Single-Center Retrospective Analysis"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-2214","authenticated-orcid":false,"given":"Tatsuo","family":"Kataoka","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Services, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]},{"name":"Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7896-3732","authenticated-orcid":false,"given":"Takanori","family":"Taogoshi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]},{"name":"Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5897-3739","authenticated-orcid":false,"given":"Yoko","family":"Hiyama","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]},{"name":"Department of Microbiology, Graduate School of Biomedical and Health Sciences , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-0411","authenticated-orcid":false,"given":"Takashi","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-1896","authenticated-orcid":false,"given":"Kazutaka","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kumamoto University Hospital , Kumamoto ,","place":["Japan"]},{"name":"Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8730-5389","authenticated-orcid":false,"given":"Hiroaki","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Services, Hiroshima University Hospital , Hiroshima ,","place":["Japan"]},{"name":"Department of Pharmaceutical Services, Graduate School of Biomedical and Health Sciences, Hiroshima University , Hiroshima ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"2026081811271085700_ref1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/jac\/dkaf097","article-title":"Appropriateness of loading dose and TDM in patients treated with teicoplanin: a single-centre observational retrospective cohort study comparing single-daily and thrice-weekly regimens","volume":"80","author":"Behring","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026081811271085700_ref2","first-page":"CD007022","volume":"16","author":"Cavalcanti","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026081811271085700_ref3","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081811271085700_ref4","volume-title":"Clinical Practice Guidelines for the Management of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, 2024 Edition","author":"Japanese Association for Infectious Diseases (JAID), Japanese Society of Chemotherapy (JSC)","year":"2024"},{"key":"2026081811271085700_ref5","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026081811271085700_ref6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026081811271085700_ref7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijantimicag.2012.05.025","article-title":"Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation","volume":"40","author":"Yamada","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2026081811271085700_ref8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1128\/AAC.32.8.1223","article-title":"Pharmacokinetics of teicoplanin in pediatric patients","volume":"32","author":"Terragna","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081811271085700_ref9","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/jac\/dkt176","article-title":"Age- and gender-related differences in teicoplanin levels in paediatric patients","volume":"68","author":"Strenger","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026081811271085700_ref10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/bcp.12710","article-title":"Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease","volume":"80","author":"Zhao","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2026081811271085700_ref11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/FTD.0000000000000930","article-title":"Optimal Teicoplanin dosing regimen in neonates and children developed by leveraging real-world clinical information","volume":"44","author":"Yamada","year":"2022","journal-title":"Ther Drug Monit"},{"key":"2026081811271085700_ref12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper#","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2026081811271085700_ref13","doi-asserted-by":"crossref","first-page":"594562","DOI":"10.3389\/fphar.2020.594562","article-title":"Population pharmacokinetics and model-based dosing optimization of teicoplanin in pediatric patients","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026081811271085700_ref14","first-page":"7","article-title":"Four times loading dose of teicoplanin achieves an effective serum concentration in pediatric cases","volume":"63","author":"Kataoka","year":"2015","journal-title":"Jpn J Chemother"},{"key":"2026081811271085700_ref15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.mpmed.2020.04.012","article-title":"Pharmacokinetics for the prescriber","volume":"48","author":"McLeod","year":"2020","journal-title":"Medicine"},{"key":"2026081811271085700_ref16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"39","author":"Wilson","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"2026081811271085700_ref17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fphar.2020.00552","article-title":"Population pharmacokinetics and dosage optimization of Teicoplanin in children with different renal functions","volume":"11","author":"Gao","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026081811271085700_ref18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/00006454-199606000-00005","article-title":"Teicoplanin pharmacokinetics in pediatric patients","volume":"15","author":"Dufort","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"2026081811271085700_ref19","first-page":"1","article-title":"Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation (HSCT)","volume":"7","author":"Ghehi","year":"2013","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"2026081811271085700_ref20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10157-013-0856-y","article-title":"Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease","volume":"18","author":"Uemura","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"2026081811271085700_ref21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10157-017-1460-3","article-title":"Creatinine-based estimated glomerular filtration rate for children younger than 2 years","volume":"22","author":"Uemura","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2026081811271085700_ref22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12185-025-04053-6","article-title":"Validation of an algorithm for identifying patients with febrileneutropenia: an epidemiological study using real-world data in Japan","volume":"123","author":"Ishikawa","year":"2026","journal-title":"Int J Hematol"},{"key":"2026081811271085700_ref23","volume-title":"CTCAE and Adverse Event Reporting","author":"Cancer Therapy Evaluation Program"},{"key":"2026081811271085700_ref24","doi-asserted-by":"publisher","first-page":"101214","DOI":"10.1016\/j.lanepe.2025.101214","article-title":"2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies","volume":"51","author":"Sandherr","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026081811271085700_ref25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2014concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"2026081811271085700_ref26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/FTD.0000000000000978","article-title":"Association of vancomycin trough concentration and clearance with febrile neutropenia in Pediatric patients","volume":"44","author":"Amano","year":"2022","journal-title":"Ther Drug Monit"},{"key":"2026081811271085700_ref27","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/jac\/dkab302","article-title":"Population pharmacokinetics of vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations","volume":"76","author":"Shimamoto","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026081811271085700_ref28","first-page":"376","article-title":"Safety analysis of teicoplanin trough concentrations of over 15 \u03bcg\/mL, and evaluation of the recommended loading dose regimen to rapidly achieve optimal concentrations in pediatric patients","volume":"67","author":"Risa","year":"2019","journal-title":"Jpn J Chemother"},{"key":"2026081811271085700_ref29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/medicina59040758","article-title":"Accuracy of therapeutic drug monitoring of Teicoplanin at the onset of febrile neutropenia","volume":"59","author":"Takigawa","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026081811271085700_ref30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/antibiotics14060570","article-title":"Impact of recovery from febrile neutropenia on intra-individual variability in vancomycin pharmacokinetics in Pediatric patients","volume":"14","author":"Takumi","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"2026081811271085700_ref31","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70519","article-title":"Population pharmacokinetics and Monte Carlo simulation of cefepime in paediatric and young adult bone marrow transplant patients","volume":"92","author":"Morales","year":"2026","journal-title":"Br J Clin Pharmacol"},{"key":"2026081811271085700_ref32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40780-026-00550-w","article-title":"Predictors of target initial teicoplanin trough concentration attainment in patients with hematological malignancies: a retrospective cohort study","volume":"12","author":"Deguchi","year":"2026","journal-title":"J Pharm Health Care Sci"},{"key":"2026081811271085700_ref33","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1023\/B:PHAM.0000048198.56873.d8","article-title":"Pharmacokinetics of Teicoplanin in an ICU population of children and infants","volume":"21","author":"Lukas","year":"2004","journal-title":"Pharm Res"},{"key":"2026081811271085700_ref34","first-page":"131","article-title":"Clinical phenotypes and glycopeptide escalation patterns in pediatric febrile neutropenia: associations with short-term outcomes and acute kidney injury risk","volume":"43","author":"Tahta","year":"2026","journal-title":"Turk J Hematol"},{"key":"2026081811271085700_ref35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/sj.bmt.1705412","article-title":"Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation","volume":"38","author":"Caliskan","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2026081811271085700_ref36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jiac.2021.10.008","article-title":"Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients","volume":"28","author":"Mikami","year":"2022","journal-title":"J Infect Chemother"},{"key":"2026081811271085700_ref37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40262-020-00945-4","article-title":"Population pharmacokinetics of unbound and total teicoplanin in critically ill Pediatric patients","volume":"60","author":"Aulin","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2026081811271085700_ref38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/FTD.0000000000001302","article-title":"Investigation of teicoplanin trough concentrations and safety following high-dose loading in a pediatric population","volume":"47","author":"Okuzono","year":"2025","journal-title":"Ther Drug Monit"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piag069\/70558802\/piag069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piag069\/70558802\/piag069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piag069\/70558802\/piag069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:29:34Z","timestamp":1787066974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piag069\/8756987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piag069","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"piag069"}}